(Q44124135)

30 November 2017

title

Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma (English)

1 reference

30 November 2017

4

Christian Stief

1 reference

30 November 2017

Jens Atzpodien

1

1 reference

30 November 2017

Reinhard Hoffmann

2

1 reference

30 November 2017

Marcus Franzke

3

1 reference

30 November 2017

Thomas Wandert

5

1 reference

30 November 2017

Martina Reitz

6

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

30 November 2017

1 reference

30 November 2017

volume

95

1 reference

30 November 2017

issue

5

1 reference

30 November 2017

page(s)

1045-1050

1 reference

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in the treatment of metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administrat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

Renal cell carcinoma: natural history and results of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

7 January 2021

Prognostic factors in metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

7 January 2021

Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

7 January 2021

Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

7 January 2021

Response to 13-cis-retinoic acid plus interferon alfa-2a in two patients with therapy-refractory advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

7 January 2021

Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

7 January 2021

Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

7 January 2021

Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10783

7 January 2021

Identifiers

DOI

10.1002/CNCR.10783

1 reference

30 November 2017

1 reference